# In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease

> **NCT05974345** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 204691 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** Inclisiran sodium
- **DRUG:** Placebo
- **DRUG:** Ezetimibe
- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT05974345
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-03
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 204691 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05974345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05974345, "In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05974345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*